Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid Shrinkage
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-18. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Lower medical loss ratios lift CNC earnings per share to $2.51, mitigating top-line headwinds from a projected 8% to 9% Medicaid membership roll-off.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factCentene posted second-quarter 2026 adjusted EPS of $2.51, rebounding from a net loss in the year-ago period. |
| What else was confirmed? | Reported factUnderwriting improvement was driven by medical cost moderation and operating execution. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for CNC; the latest is dated 2026-09-16. |
| What would change the assessment? | UnknownState Medicaid redetermination reporting — State health authority disclosures on Medicaid enrollment attrition rates |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Centene posted second-quarter 2026 adjusted EPS of $2.51, rebounding from a net loss in the year-ago period.
- · Underwriting improvement was driven by medical cost moderation and operating execution.
- · Management forecasts full-year 2026 Medicaid membership will contract by 8% to 9%, offset by margin expansion in Health Insurance Marketplace and Medicare lines.
Public research record
Research framework · page evidenceCompleted event assessment
medical loss ratio normalization and EPS recovery
| Type | Claim | Scope |
|---|---|---|
| Assumption | Centene posted second-quarter 2026 adjusted EPS of $2.51, rebounding from a net loss in the year-ago period. | 2026-09-18 |
| Interpretation | medical loss ratio normalization and EPS recovery | CNC |
Countercase, invalidators, and sources
Commercial Marketplace margins outpace Medicaid enrollment declines, lifting full-year EPS guidance.
- · State Medicaid redetermination reporting — State health authority disclosures on Medicaid enrollment attrition rates
- Can Centene Sustain Its Turnaround Amid Membership Pressure? · 2026-09-17
What remains unresolved
- Base path
- Medicaid membership stabilizes within the guided negative 8% to 9% range with controlled medical loss ratios.
- Adverse path
- Unexpected medical cost spikes in Medicare Advantage compress operating margins below Q2 levels.
- Supportive path
- Commercial Marketplace margins outpace Medicaid enrollment declines, lifting full-year EPS guidance.
- · State Medicaid redetermination reporting — State health authority disclosures on Medicaid enrollment attrition ratesthis week
Evidence
- Can Centene Sustain Its Turnaround Amid Membership Pressure?2026-09-17
“Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior... expects Medicaid membership to decline 8%-9% in 2026...”
Supports: Centene reported Q2 2026 adjusted EPS of $2.51, recovering from a year-ago loss, with Medicaid membership projected to decline 8%-9%.